reports
MediWound to Report Second Quarter 2025 Financial Results
MediWound to Report Second Quarter 2025 Financial Results MediWound to Report Second Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time YAVNE, Israel, August 4, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025. Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time...
MediWound Reports First Quarter 2025 Financial Results and Provides Co...
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update VALUE Phase III trial of EscharEx® in venous leg ulcers advancing as planned NexoBrid® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue of $4 million; full-year 2025 revenue guidance reaffirmed at $24 million Conference call today, May 21 at 8:30am Eastern Time YAVNE, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial res...
MediWound Announces Publication of Phase II EscharEx® Data Demonstrati...
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL® YAVNE, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post hoc analysis in Wounds. The analysis is based on data from the Company’s Phase II ChronEx clinical t...
MediWound to Report First Quarter 2025 Financial Results
MediWound to Report First Quarter 2025 Financial Results Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time YAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 21, 2025. Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial resul...
MediWound to Present New EscharEx® Data at Leading Wound Care Conferen...
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences Presentations at WHS and SAWC to highlight EscharEx’s mechanism of action, preclinical advantages over SANTYL®, and new data in treating VLUs and DFUs Findings reinforce the ongoing Phase III study in VLUs and support the planned DFU trial strategy YAVNE, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will present 10 scientific abstracts—including both oral and poster pres...
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results ...
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for 2024; $24 million projected for 2025; $44 million in cash as of Year-End 2024 Conference call today, March 19 at 8:30am Eastern Time YAVNE, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, t...
MediWound to Report Fourth Quarter and Full Year 2024 Financial Result...
MediWound to Report Fourth Quarter and Full Year 2024 Financial Results Conference call and webcast scheduled for Wednesday, March 19th at 8:30 a.m. Eastern Time YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, March 19, 2025. Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to ...
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediat...
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care Findings in Burns Journal confirm NexoBrid’s superiority over standard of care in pediatric patients with deep thermal burnsNexoBrid is approved for pediatric use in the U.S., E.U. and Japan YAVNE, Israel, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of its Phase III Children Innovative Debridement Study (CIDS) in , the peer-reviewed Journal of the International Society for Burn Injuries...
MediWound to Present at the 45th Annual TD Cowen Health Care Conferenc...
MediWound to Present at the 45th Annual TD Cowen Health Care Conference YAVNE, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will present a corporate overview at the upcoming 45th Annual TD Cowen Health Care Conference, taking place in Boston, MA on Wednesday, March 5, 2025, at 11:50 AM ET. To listen to the live webcast of the presentation, please register . A replay of the event will also be posted to MediWound’s website on the ...
MediWound Initiates the VALUE Global Phase III Pivotal Trial of Eschar...
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in mid-2026 Strategic research collaborations with Solventum, Mölnlycke, and MIMEDX YAVNE, Israel, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the initiation of VALUE, a gl...
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Lif...
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will take part in a fireside chat during the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual). The fireside chat, hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer, will take place on Wednesday, February 12, ...
MediWound Ltd: 1 director
A director at MediWound Ltd bought 18,462 shares at 17.130USD and the significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx...
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025 YAVNE, Israel, Dec. 17, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced it will host a virtual Key Opinion Leader (KOL) event on Wednesday, January 8, 2025, at 10:00 AM ET. The event will focus on EscharEx®, an innovative biologic drug in late-stage clinical development for chronic wound debridement, including the upcoming Phas...
MediWound Reports Third Quarter 2024 Financial Results and Provides Co...
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025 FDA Approves NexoBrid for Pediatric Use $25 Million Financing and €16.25 Million EIC Funding Strengthen Cash Runway to Profitability NexoBrid Product Revenue Meets Expectations; Demand Exceeds Capacity as New Manufacturing Facility Commissioning Underway Conference Call Today, November 26 at 8:30 a.m. Eastern Time YAVNE, Israel, Nov. 26, 2024 (GLOBE NEWSWIRE) -- MediWoun...
MediWound to Report Third Quarter 2024 Financial Results
MediWound to Report Third Quarter 2024 Financial Results Conference Call and Webcast Scheduled for Tuesday, November 26, 2024, at 8:30 a.m. Eastern Time YAVNE, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the third quarter ended September 30, 2024, on Tuesday, November 26, 2024. Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financia...
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® v...
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers Secured additional R&D collaborations with Solventum and Mölnlycke for optimal trial consistency and patient outcomes Study to support EscharEx® BLA submission and strengthen commercialization strategy YAVNE, Israel, Oct. 10, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will be initiating a controlled, multicenter Phase II clinical study evaluating EscharEx...
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit YAVNE, Israel, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will take part in a fireside chat during the 2024 Maxim Healthcare Virtual Summit. The fireside chat, hosted by Michael Okunewitch, Senior Biotechnology Analyst at Maxim, will take place on Wednesday, October 16, 2024, at 9:30 a.m. ET. To attend the virtual fireside chat, please register . In addition, the Medi...
MediWound to Present at the H.C. Wainwright 26th Annual Global Investm...
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference YAVNE, Israel, Sept. 03, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research, on Tuesday, September 10, 2024 at 3:30 p.m. ET at the H.C. Wainwright 26th Annual Global Investment Conference. A live webcast of the event will be accessible both and on M...
MediWound Announces U.S. Food and Drug Administration Approval of Nexo...
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages YAVNE, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for NexoBrid® (anacaulase-bcdb) allowing for eschar removal in pediatr...
MediWound Reports Second Quarter 2024 Financial Results and Provides C...
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update Completed Construction of New NexoBrid® Manufacturing Facility €16.25 Million EIC Funding Expedites EscharEx® Development for Diabetic Foot Ulcers, Significantly Expanding the Addressable Market; Phase III Study for Venous Leg Ulcers to Begin in H2 2024 $25 Million Strategic Investment Led by Mölnlycke Health Care Conference Call Today, August 14 at 8:30am Eastern Time YAVNE, Israel, Aug. 14, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-gener...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.